Replies to post #170623 on Biotech Values

[jbog]

All of Teva’s current problems can be traced, directly or indirectly, to the impending loss of one of the most profitable drug franchises of all time.

No question that Copaxone is causing trouble but that has to be expected, they also face the fact that their generic business is under pressure.